If you work in a pharma or biotech lab, you have used Bio Techne products. The recombinant proteins that populate your assay panels. The antibodies that validate your targets. The reagents that power your diagnostic platforms. The cytokines and growth factors that make your cell culture work. Merck KGaA (which operates as MilliporeSigma in the U.S. for its life sciences business) just agreed to acquire Bio Techne for $11.3 billion—its largest deal in more than a decade—to deepen its position as an essential supplier to the drug discovery industry.
This is a different kind of life sciences M&A. Not a drug pipeline acquisition. Not a clinical stage asset purchase. This is a company buying the tools that make drug discovery possible. And the timing makes sense: the ADC wave, molecular glue development, in vivo CAR T, AI driven target discovery—every major trend in biopharma this year increases demand for the high quality research reagents that Bio Techne supplies. Meanwhile, Revolution Medicines showed its pipeline extends beyond daraxonrasib. The RM-055 catalytic RAS(ON) inhibitor doubled the chemotherapy response rate in pancreatic cancer in early combination data. Two drugs for the same cancer, with different mechanisms, from the same company. That is a franchise, not a one product story. Takeda formally appointed Julie Kim as CEO. Ionis got the first treatment approved for pancreatitis risk in severe hypertriglyceridemia. And the FDA is hiring 2,200 people to rebuild after last year’s DOGE related workforce cuts.
Merck KGaA Acquires Bio Techne for $11.3B
What Happened: Merck KGaA agreed to acquire Bio Techne Corp for $11.3 billion, expanding its life sciences tools and research reagent portfolio. This is the biggest life sciences tools acquisition of 2026 and Merck KGaA’s largest deal in more than a decade.
What Bio Techne Actually Does
Bio Techne is not a household name outside the industry, but its products are in nearly every drug discovery lab in the world. The company provides recombinant proteins, monoclonal and polyclonal antibodies, immunoassay kits, molecular biology tools, and advanced diagnostic instruments to researchers in pharmaceutical companies, biotech startups, and academic institutions.
The products sound mundane until you realize they are the foundation of almost every drug discovery workflow. A researcher validating a new target needs antibodies and proteins from Bio Techne’s catalog. A company developing an ADC needs the target proteins to test binding specificity. A molecular glue program needs the ligase proteins and target proteins to screen for productive interactions. An in vivo CAR T program needs cytokines and growth factors for cell engineering. A diagnostics company developing a companion test for PTEN (like AstraZeneca’s Truqap approval we covered last week) needs the immunohistochemistry reagents that Bio Techne supplies.
The deal strengthens Merck KGaA’s MilliporeSigma business alongside competitors like Danaher, Thermo Fisher Scientific, and Agilent Technologies in the $80 billion plus global life sciences tools market. The competitive dynamics in this space are driven by catalog breadth (the company with the most products wins the most orders), reagent quality (inconsistent reagents waste researchers’ time and money), and global distribution (labs need same day or next day delivery to keep experiments on schedule).
Why Merck KGaA Is Making This Bet Now
The timing connects to every major trend we have tracked in 2026. The ADC wave (Enhertu, Datroway, sac TMT, Padcev, CrossBridge) requires extensive target protein and antibody characterization during development. Molecular glue programs (Novartis’s $7.1 billion commitment across four deals) need sophisticated protein interaction screening tools. AI drug discovery platforms (Anthropic, Isomorphic, Inceptive, Profluent) generate computational predictions that must be validated with wet lab experiments using the kind of reagents Bio Techne manufactures. The more active the drug discovery landscape becomes, the more reagents and tools it consumes.
For Merck KGaA, which already operates one of the world’s largest life sciences supply businesses through MilliporeSigma, adding Bio Techne creates a more comprehensive tools platform. The combined entity would supply chemicals, solvents, cell culture media (existing MilliporeSigma products), proteins, antibodies, cytokines, and diagnostic reagents (Bio Techne products) under one organizational umbrella. The cross selling opportunity is meaningful: labs that already buy chemicals from MilliporeSigma would now also buy their research proteins and antibodies from the same company.
For drug developers: this deal means Bio Techne’s product catalog, pricing, and customer support will eventually operate under the Merck KGaA umbrella. Whether that improves or complicates the purchasing experience remains to be seen. Integration of tools companies can be disruptive for customers who depend on consistent product quality and supply reliability.
Our Pro brief analyzes why Merck KGaA paying $11.3B for Bio Techne matters for every company that buys research reagents, how the deal fits the broader life sciences tools consolidation wave, and what it means for Bio Techne customers. [Details below.]
Revolution’s Second RAS Drug Doubles Chemo Response in Pancreatic Cancer
What Happened: BioSpace reported on June 25 that Revolution Medicines’ RM-055, a catalytic RAS(ON) inhibitor with a different mechanism than daraxonrasib, doubled the chemotherapy response rate in pancreatic cancer in early combination data.
Two Drugs, Two Mechanisms, One Disease
This positions Revolution as a two drug pancreatic cancer franchise. The distinction between the two drugs matters:
Daraxonrasib (RASolute 302, OS HR 0.40, CNPV filing imminent) targets RAS in its active state. The drug binds the RAS protein when it is in the “on” configuration that drives tumor growth, blocking the signaling cascade that tells cancer cells to proliferate. The Phase 3 data are practice changing: median OS doubled from 6.7 to 13.2 months in second line pancreatic cancer. NEJM published. FDA expanded access granted. Truist projects Q3 approval.
RM-055 targets the catalytic function of RAS through a different binding mechanism. By approaching the same target through a different molecular interaction, RM-055 has the potential to work in patients who develop resistance to daraxonrasib (because resistance mutations that block one binding mode may not block the other) and to combine with daraxonrasib for deeper responses than either drug alone.
Early combination data showing the drug doubled the chemo response rate is a promising signal, though early data must be interpreted cautiously. The data join the 58% overall response rate in first line pancreatic cancer that Revolution presented at AACR in April (daraxonrasib plus chemotherapy).
What a Two Drug Franchise Means
Twelve months ago, pancreatic cancer had no targeted therapies. Zero. The disease had resisted every precision medicine approach that transformed lung cancer, breast cancer, melanoma, and other solid tumors. Today, Revolution has three distinct data packages in pancreatic cancer: second line monotherapy (daraxonrasib, Phase 3 positive), first line combination (daraxonrasib plus chemo, 58% ORR at AACR), and a second mechanism combination (RM-055 plus chemo, doubled response rate).
If both drugs reach the market, Revolution could offer sequential treatment (daraxonrasib first, RM-055 at resistance) or combination treatment (both drugs together for maximum response) that no other oncology company can match in this disease. That is a franchise. And it is being built in a cancer that kills more than 50,000 Americans per year with a five year survival rate below 15%.
Takeda Formally Appoints Julie Kim as CEO
What Happened: Takeda formally appointed Julie Kim as president and CEO on June 25, completing an 18 month leadership transition at Japan’s largest pharmaceutical company.
Why This Matters: Kim takes the helm as Takeda executes a transformation program that includes 4,500 global job cuts (announced May), portfolio simplification, and a strategic pivot toward GI, neuroscience, and rare disease. She is the first woman to lead Takeda and one of the few female CEOs of a top 20 global pharmaceutical company.
The transition comes at a complex moment for Takeda. The company is simplifying its portfolio after years of diversification, reducing headcount to focus resources on the therapeutic areas where it has the deepest expertise, and navigating the same patent cliff and M&A dynamics that are driving the rest of the industry. Kim’s leadership will be measured by whether the transformation program produces a more focused, faster growing Takeda—or whether the cuts and simplification come at the cost of pipeline depth and innovation capacity.
Ionis Tryngolza Approved for Severe Hypertriglyceridemia
What Happened: The FDA approved Ionis Pharmaceuticals’ Tryngolza (olezarsen) as the first treatment to reduce the risk of acute pancreatitis in patients with severe hypertriglyceridemia (triglycerides at or above 500 mg/dL).
Why This Matters: Severe hypertriglyceridemia is a metabolic condition that dramatically increases the risk of acute pancreatitis—a painful and potentially life threatening inflammation of the pancreas. Until Tryngolza, there was no approved therapy specifically indicated to reduce this risk. Patients relied on fibrates, omega 3 fatty acids, and dietary modification, none of which were approved for pancreatitis risk reduction specifically.
Tryngolza is an antisense oligonucleotide targeting apolipoprotein C III (apoC III), a protein that regulates triglyceride metabolism. By reducing apoC III production, the drug lowers triglyceride levels at their upstream source rather than managing them through downstream lipid modification.
For Ionis, which has built its franchise on the antisense oligonucleotide platform (Spinraza for SMA with Biogen, multiple cardiometabolic programs), Tryngolza adds another approved product to a growing commercial portfolio and validates the company’s expansion into cardiovascular and metabolic disease.
FDA Hiring 2,200 to Rebuild After DOGE Cuts
What Happened: The FDA is hiring approximately 2,200 people to rebuild staffing after last year’s DOGE related workforce reductions, according to BioSpace reporting from BIO International.
Why This Matters: The hiring initiative is the most concrete sign that the FDA is attempting to restore operational capacity after the leadership disruptions and staff departures that have defined the agency throughout 2026. BioSpace also reported from BIO that the FDA’s IND initiative “is a step toward normalization after slipshod year.”
The agency is still operating without a permanent commissioner, CDER director, or CBER director. Capital Alpha called the leadership situation “the most damaging period in FDA history.” Drug Topics reported five CDER heads in one year. BioSpace reported fewer than half of senior leaders from six months ago remain. Hiring 2,200 people does not solve the leadership vacuum at the top, but it does address the operational capacity that was lost when career staff departed or were not replaced during the DOGE driven restructuring.
For the industry, the hiring is a positive signal. Review divisions, clinical evaluation teams, and regulatory support staff are the people who actually process NDAs, BLAs, and PDUFA actions. The leadership sets direction, but the career staff do the work. Rebuilding that workforce is essential for the FDA to maintain the review timelines that companies like Revolution Medicines, Lilly (Foundayo T2D), and dozens of others depend on.
Strategic Themes
1. The Life Sciences Tools Deal Reminds Us That Drug Discovery Depends on a Supply Chain Most People Never Think About
Every breakthrough we have covered this year—daraxonrasib, retatrutide, sac TMT, Enhertu, ivonescimab—was discovered and developed using proteins, antibodies, and reagents from companies like Bio Techne. The tools are invisible to most observers, but they are as essential as the drugs themselves. Merck KGaA paying $11.3 billion for Bio Techne is a bet that the drug discovery supply chain has as much durable value as any individual drug. That bet is almost certainly right. Drug programs fail. The tools to discover them are always needed.
2. Revolution Is Building a Multi Drug Pancreatic Cancer Franchise in a Disease That Had Nothing 12 Months Ago
Daraxonrasib doubled OS in second line. The daraxonrasib plus chemo combination produced 58% ORR in first line. RM-055 doubled the chemo response rate through a different mechanism. Three data packages. Two drugs. One company. One disease that has resisted every therapeutic approach for decades. If Revolution executes on this franchise, it will have done something that no oncology company has accomplished in pancreatic cancer: built a multi drug platform that addresses the disease across treatment lines and resistance settings.
3. Takeda’s New CEO Inherits a Transformation That Will Define the Company for a Decade
Julie Kim becomes CEO of Japan’s largest pharmaceutical company at a moment when the company is cutting 4,500 jobs, simplifying its portfolio, and pivoting toward three therapeutic areas. The decisions she makes in the next 12 to 18 months—what to keep, what to cut, what to acquire, and how to compete against Western pharma companies that are spending tens of billions on pipeline acquisition—will determine whether Takeda emerges as a more focused competitor or shrinks into a regional player.
4. The FDA Hiring 2,200 People Is Necessary but Not Sufficient
Rebuilding the career staff addresses operational capacity. It does not address the leadership vacuum. The FDA needs a permanent commissioner, a permanent CDER director, and a permanent CBER director. Until those positions are filled with experienced leaders who have the authority and institutional knowledge to make decisions on contentious applications, resolve inter division disputes, and set regulatory priorities, the agency will function but will not lead. Hiring 2,200 people puts bodies in seats. Appointing permanent leaders puts authority in the building.
Frequently Asked Questions
What is the Merck KGaA/Bio Techne deal?
Merck KGaA is acquiring Bio Techne for $11.3 billion. Bio Techne makes recombinant proteins, antibodies, reagents, and instruments used by pharma and biotech labs worldwide. The deal strengthens Merck KGaA’s MilliporeSigma life sciences tools business in an $80 billion plus global market.
What is Revolution’s RM-055?
A catalytic RAS(ON) inhibitor with a different mechanism than daraxonrasib. Early combination data doubled the chemotherapy response rate in pancreatic cancer. Positions Revolution as a two drug pancreatic cancer franchise alongside daraxonrasib (CNPV filing imminent, Truist projects Q3 approval).
Who is Takeda’s new CEO?
Julie Kim. Formally appointed June 25 after an 18 month transition. First woman to lead Takeda. Inherits a transformation program including 4,500 global cuts and a pivot to GI, neuroscience, and rare disease.
What is Tryngolza?
Ionis Pharmaceuticals’ olezarsen. First treatment approved to reduce the risk of acute pancreatitis in patients with severe hypertriglyceridemia. Antisense oligonucleotide targeting apoC III.
Is the FDA rebuilding?
The agency is hiring approximately 2,200 people after DOGE related cuts. The hiring addresses operational capacity but does not fill the leadership vacancies (commissioner, CDER director, CBER director) that have persisted throughout 2026.
When does the Medicare GLP 1 Bridge launch?
July 1. Six days out. Both Lilly and Novo products covered at $50 per month copay.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Life Sciences Tools M&A. We analyze why Merck KGaA paying $11.3B for Bio Techne matters for every company that buys research reagents, how the deal fits the broader tools consolidation wave alongside Danaher, Thermo Fisher, and Agilent, and what it means for Bio Techne customers during integration.
Revolution’s Two Drug Franchise. We map daraxonrasib and RM-055 across three distinct clinical data packages in pancreatic cancer, assess how two drugs with different mechanisms create sequential and combination treatment options, and model the franchise revenue potential in a disease that had zero targeted therapies one year ago.
H1 2026 Final Scorecard. We compile the definitive numbers for the most active first half in biopharma history: M&A totals, deal counts, IPO proceeds, CNPV approvals, clinical milestones, and the regulatory events that shaped the industry through June.
Plus: Takeda transformation under Kim, Ionis Tryngolza cardiovascular positioning, FDA hiring assessment, Revolution filing watch, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
